This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg
Annals of Hematology Open Access 12 April 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vizmanos JL, Ormazabal C, Larrayoz MJ, Cross NC, Calasanz MJ . JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia 2006; 20: 534–535.
Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–1953.
Boissinot M, Lippert E, Girodon F, Dobo I, Fouassier M, Masliah C et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 2006; 108: 3223–3224.
Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130: 2031–2038.
Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528–1534.
Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107: 4139–4141.
Remacha AF, Estivill C, Sarda MP, Mateo J, Souto JC, Canals C et al. The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica 2007; 92: 285–286.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pardanani, A., Lasho, T., Schwager, S. et al. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder. Leukemia 21, 1828–1829 (2007). https://doi.org/10.1038/sj.leu.2404710
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404710
This article is cited by
-
JAK2V617F Mutation in Patient with Splanchnic Vein Thrombosis
Indian Journal of Hematology and Blood Transfusion (2020)
-
The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis
Pathology & Oncology Research (2016)
-
Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg
Annals of Hematology (2012)
-
No evidence of frequent association of the JAK2 V617F mutation with acute myocardial infarction in young patients
Leukemia (2009)
-
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
Leukemia (2008)